Serum Ghrelin Level and TNF-α/Ghrelin Ratio in Patients with Previous Myocardial Infarction

Archives of Medical Research

Volumn 43, Issue 7, 2012, Pages 548-554

  Vörös, Krisztián ^a   Prohászka, Zoltán ^b   Kaszás, Edit ^c   Alliquander, Anna ^c   Terebesy, András ^a   Horváth, Ferenc ^a   Janik, Leonard ^a   Sima, Ágnes ^a   Forrai, Judit ^a   Cseh, Károly ^a,c   Kalabay, László ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c Károlyi Sándor Municipal Hospital   (Hungary)

Author keywords

Adiponectin; Ghrelin; Insulin; Myocardial infarction; Tumor necrosis factor

Indexed keywords

ADIPONECTIN; FETUIN A; GHRELIN; INSULIN; LEPTIN; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; GLUCOSE METABOLISM; HEART INFARCTION; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN METABOLISM; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RADIOIMMUNOASSAY;

ADIPONECTIN; AGED; ALPHA-2-HS-GLYCOPROTEIN; ATHEROSCLEROSIS; BLOOD GLUCOSE; BODY WEIGHT; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GHRELIN; HUMANS; INSULIN; LEPTIN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RESISTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84869820009     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2012.09.002     Document Type: Article

References (44)

1. Pulkkinen L., Ukkola O., Kolehmainen M., et al. Ghrelin in diabetes and metabolic syndrome. Int J Pept 2010, 2010. 10.1155/2010/248948.
2. Zhang G., Yin X., Qi Y., et al. Ghrelin and cardiovascular diseases. Curr Cardiol Rev 2010, 6:62-70.
3. Kishimoto I., Tokudome T., Hosoda H., et al. Ghrelin and cardiovascular diseases. J Cardiol 2012, 59:8-13.
4. Kadoglou N.P., Sailer N., Moumtzouoglou A., et al. Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2010, 118:75-80.
5. Yano Y., Toshinai K., Inokuchi T., et al. Plasma des-acyl ghrelin, but not plasma HMW adiponectin, is a useful cardiometabolic marker for predicting atherosclerosis in elderly hypertensive patients. Atherosclerosis 2009, 204:590-594.
6. Kotani K., Sakane N., Saiga K., et al. Serum ghrelin and carotid atherosclerosis in older Japanese people with metabolic syndrome. Arch Med Res 2006, 37:903-906.
7. Kadoglou N.P., Lampropoulos S., Kapelouzou A., et al. Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease-KOZANI STUDY. Transl Res 2010, 155:238-246.
8. Poykko S.M., Kellokoski E., Ukkola O., et al. Plasma ghrelin concentrations are positively associated with carotid artery atherosclerosis in males. J Intern Med 2006, 260:43-52.
9. Ukkola O., Poykko S., Paivansalo M., et al. Interactions between ghrelin, leptin and IGF-I affect metabolic syndrome and early atherosclerosis. Ann Med 2008, 40:465-473.
10. Haffner S.M., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
11. Tong J., Prigeon R.L., Davis H.W., et al. Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes 2010, 59:2145-2151.
12. Poykko S.M., Kellokoski E., Horkko S., et al. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003, 52:2546-2553.
13. Krzyzanowska-Swiniarska B., Kempa A., Miazgowski T., et al. Serum acylated ghrelin, adiponectin and leptin levels in normal-weight and obese premenopausal women. Horm Metab Res 2007, 39:835-839.
14. Kiewiet R.M., Hazell M.J., Van Aken M.O., et al. Acute effects of acylated and unacylated ghrelin on total and high molecular weight adiponectin in morbidly obese subjects. J Endocrinol Invest 2011, 34:434-438.
15. Caliskan Y., Gorgulu N., Yelken B., et al. Plasma ghrelin levels are associated with coronary microvascular and endothelial dysfunction in peritoneal dialysis patients. Ren Fail 2009, 31:807-813.
16. Erdmann J., Lippl F., Wagenpfeil S., et al. Differential association of basal and postprandial plasma ghrelin with leptin, insulin, and type 2 diabetes. Diabetes 2005, 54:1371-1378.
17. Corrado E., Rizzo M., Coppola G., et al. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb 2010, 17:1-11.
18. Hattori N. Expression, regulation and biological actions of growth hormone (GH) and ghrelin in the immune system. Growth Horm IGF Res 2009, 19:187-197.
19. Baatar D., Patel K., Taub D.D. The effects of ghrelin on inflammation and the immune system. Mol Cell Endocrinol 2011, 340:44-58.
20. Kalabay L., Jakab L., Prohaszka Z., et al. Human fetuin/alpha2HS-glycoprotein level as a novel indicator of liver cell function and short-term mortality in patients with liver cirrhosis and liver cancer. Eur J Gastroenterol Hepatol 2002, 14:389-394.
21. Tschop M., Weyer C., Tataranni P.A., et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001, 50:707-709.
22. Meyer C. Final answer: ghrelin can suppress insulin secretion in humans, but is it clinically relevant?. Diabetes 2010, 59:2726-2728.
23. Palik E., Baranyi E., Melczer Z., et al. Elevated serum acylated (biologically active) ghrelin and resistin levels associate with pregnancy-induced weight gain and insulin resistance. Diabetes Res Clin Pract 2007, 76:351-357.
24. Saad M.F., Bernaba B., Hwu C.M., et al. Insulin regulates plasma ghrelin concentration. J Clin Endocrinol Metab 2002, 87:3997-4000.
25. Broglio F., Gottero C., Prodam F., et al. Ghrelin secretion is inhibited by glucose load and insulin-induced hypoglycaemia but unaffected by glucagon and arginine in humans. Clin Endocrinol 2004, 61:503-509.
26. An W., Li Y., Xu G., et al. Modulation of ghrelin O-acyltransferase expression in pancreatic islets. Cell Physiol Biochem 2010, 26:707-716.
27. Sondergaard E., Gormsen L.C., Nellemann B., et al. Visceral fat mass is a strong predictor of circulating ghrelin levels in premenopausal women. Eur J Endocrinol 2009, 160:375-379.
28. Anderwald C., Brabant G., Bernroider E., et al. Insulin-dependent modulation of plasma ghrelin and leptin concentrations is less pronounced in type 2 diabetic patients. Diabetes 2003, 52:1792-1798.
29. Soni A.C., Conroy M.B., Mackey R.H., et al. Ghrelin, leptin, adiponectin, and insulin levels and concurrent and future weight change in overweight, postmenopausal women. Menopause 2011, 18:296-301.
30. Ott V., Fasshauer M., Dalski A., et al. Direct peripheral effects of ghrelin include suppression of adiponectin expression. Horm Metab Res 2002, 34:640-645.
31. Jiang Z.T., Zou Y.P., Huang H., et al. Mechanism of laparoscopic adjustable gastric banding in the treatment of obesity with type 2 diabetes mellitus. Zhonghua Wei Chang Wai Ke Za Zhi 2010, 13:520-523.
32. Ix J.H., Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol 2010, 21:406-412.
33. Voros K., Graf L., Prohaszka Z., et al. Serum fetuin-A in metabolic and inflammatory pathways in patients with myocardial infarction. Eur J Clin Invest 2011, 41:703-709.
34. Nanjo Y., Adachi H., Hirai Y., et al. Factors associated with plasma ghrelin level in Japanese general population. Clin Endocrinol 2011, 74:453-458.
35. Palik E., Birkas K.D., Faludi G., et al. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract 2005, 68(suppl 1):S60-S64.
36. Miegueu P., St Pierre D., Broglio F., et al. Effect of desacyl ghrelin, obestatin and related peptides on triglyceride storage, metabolism and GHSR signaling in 3T3-L1 adipocytes. J Cell Biochem 2011, 112:704-714.
37. Theander-Carrillo C., Wiedmer P., Cettour-Rose P., et al. Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest 2006, 116:1983-1993.
38. Bonvini Rf H.T., Camenzind E. Inflammatory response post-myocardial infarction and reperfusion: a new therapeutic target?. Eur Heart J Suppl 2005, 7(suppl I):127-136.
39. Liehn E.A., Postea O., Curaj A., et al. Repair after myocardial infarction, between fantasy and reality: the role of chemokines. J Am Coll Cardiol 2011, 58:2357-2362.
40. Frangogiannis N.G., Smith C.W., Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc Res 2002, 53:31-47.
41. Karmiris K., Koutroubakis I.E., Xidakis C., et al. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12:100-105.
42. Toussirot E., Streit G., Nguyen N.U., et al. Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis. Metabolism 2007, 56:1383-1399.
43. Kadoglou N.P., Tsanikidis H., Kapelouzou A., et al. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. Metabolism 2010, 59:373-379.
44. Otto C., Otto B., Frost R.J., et al. Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta Diabetol 2007, 44:65-68.